Recherche

Afficher tous les résultats pour

Accueil

Personne

Douglas Hanahan

Cette personne a quitté l’EPFL

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (59)

Page 2 sur 3

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Ksenya Shchors, Julie Laetitia Scotton

Glioblastoma (GBM) is poorly responsive to therapy and invariably lethal. One conceivable strategy to circumvent this intractability is to co-target distinctive mechanistic components of the disease, aiming to concomitantly disrupt multiple capabilities re ...

2022

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment

Douglas Hanahan

Tumorigenesis embodies the formation of a heterotypic tumour microenvironment (TME) that, among its many functions, enables the evasion of T cell-mediated immune responses. Remarkably, most TME cell types, including cancer cells, fibroblasts, myeloid cells ...

NATURE PORTFOLIO2024

Genetic Deletion of the Desmosomal Component Desmoplakin Promotes Tumor Microinvasion in a Mouse Model of Pancreatic Neuroendocrine Carcinogenesis

Douglas Hanahan

We used the RIP1-Tag2 (RT2) mouse model of islet cell carcinogenesis to profile the transcriptome of pancreatic neuroendocrine tumors (PNET) that were either non-invasive or highly invasive, seeking to identify pro- and anti-invasive molecules. Expression ...

Public Library of Science2010

Time-resolved imaging system for fluorescence-guided surgery with lifetime imaging capability

Edoardo Charbon, Claudio Bruschini, Douglas Hanahan, Krisztian Homicsko, Riccardo Sinisi, François Eric Powolny

We present a single-photon camera for fluorescence imaging, with a time resolution better than 100ps, capable of providing both intensity and lifetime images. the camera was fabricated in standard CMOS technology. With this FluoCam we show the possibility ...

Spie-Int Soc Optical Engineering2014

Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression

Douglas Hanahan, Krisztian Homicsko, Stephan Wullschleger, Iacovos Michael, Mohammad Sadegh Saghafinia

Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics ap ...

AMER ASSOC CANCER RESEARCH2021

Method for determining cancer invasiveness and patient prognosis

Douglas Hanahan, Leanne Li

A method for determining the prognosis for survival of a patient having cancer is disclosed, said cancer being altered (i.e. highly activated or alternatively inactive/inhibited) in the NMDAR signalling pathway, said method comprising determining the expre ...

2019

Deficiency for the Cysteine Protease Cathepsin L Impairs Myc-Induced Tumorigenesis in a Mouse Model of Pancreatic Neuroendocrine Cancer

Douglas Hanahan, Ksenya Shchors

Motivated by the recent implication of cysteine protease cathepsin L as a potential target for anti-cancer drug development, we used a conditional MycER(TAM); Bcl-x(L) model of pancreatic neuroendocrine tumorigenesis (PNET) to assess the role of cathepsin ...

Public Library of Science2015

Endogenous Myc maintains the tumor microenvironment

Douglas Hanahan

The ubiquitous deregulation of Myc in human cancers makes it an intriguing therapeutic target, a notion supported by recent studies in Ras-driven lung tumors showing that inhibiting endogenous Myc triggers ubiquitous tumor regression. However, neither the ...

2011

Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis

Douglas Hanahan, Anguraj Sadanandam

Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare but clinically challenging tumor type. In particular, high grade, poorly-differentiated PanNETs have the worst patient prognosis, and the underlying mechanisms of disease are poorly understoo ...

Public Library of Science2013

Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis

Douglas Hanahan, Ksenya Shchors

Despite their apparent success in pre-clinical trials, metalloproteinase (MMP) inhibitors proved to be inefficacious in clinical settings. In an effort to understand the underlying causes of this unanticipated outcome, we modeled the consequences of long-t ...

2013

Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors

Douglas Hanahan

The cathepsin family of lysosomal proteases is increasingly being recognized for their altered expression in cancer and role in facilitating tumor progression. The aspartyl protease cathepsin E is overexpressed in several cancers and has been investigated ...

Walter De Gruyter Gmbh2016

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Douglas Hanahan, Mélanie Louise Tichet, Krisztian Homicsko, Stephan Wullschleger, Agnieszka Alicja Chryplewicz

Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most pa-tients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects o ...

CELL PRESS2023

A pan-cancer classification based on fmrp pathway activity that informs differential prognosis and therapeutic responses

Douglas Hanahan

The present invention relates to methods and compositions which provide a companion diagnostic for cancer therapy. A method for identifying and stratifying a patient or group of patients with cancer as (i) being high or low for FMRP activity, (ii) having a ...

2022

A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis

Douglas Hanahan, Mohammad Sadegh Saghafinia, Iacovos Michael

MicroRNA-mediated gene regulation has been implicated in various diseases, including cancer. This study examined the role of microRNAs (miRNAs) during tumorigenesis and malignant progression of pancreatic neuroendocrine tumors (PanNETs) in a genetically en ...

National Academy of Sciences2019

Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit

Douglas Hanahan, Ksenya Shchors

The associations of tricyclic antidepressants (TCAs) with reduced incidence of gliomas and elevated autophagy in glioma cells motivated investigation in mouse models of gliomagenesis. First, we established that imipramine, a TCA, increased autophagy and co ...

Elsevier2015

FMRP and cancer treatment

Douglas Hanahan, Qiqun Zeng

The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention o ...

2020

Colorectal cancer classification with differential prognosis and personalized therapeutic responses

Douglas Hanahan, Anguraj Sadanandam

The present invention relates to gene sets, the expression levels of which are useful for classifying colorectal tumors and predicting disease-free prognosis and response of patients to specific therapies that are either novel or currently available in the ...

2015

Milestones in tumor vascularization and its therapeutic targeting

Michele De Palma, Douglas Hanahan

Research into the mechanisms and manifestations of solid tumor vascularization was launched more than 50 years ago with the proposition and experimental demonstrations that angiogenesis is instrumental for tumor growth and was, therefore, a promising thera ...

Nature Portfolio2024

Reconciliation of classification systems defining molecular subtypes of colorectal cancer

Douglas Hanahan, Anguraj Sadanandam

Recently we published two independent studies describing novel gene expression-based classifications of colorectal cancer (CRC). Notably, each study stratified CRC into a different number of subtypes: one reported 3 subtypes, whereas the second highlighted ...

Landes Bioscience2014

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells

Douglas Hanahan, Mélanie Louise Tichet, Petra Catalina Schwalie, Stephan Wullschleger

Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1-4). Hashimoto et al. have shown that, in chronic infections, administr ...

NATURE PORTFOLIO2022